Cognitive impairment is common in untreated MS patients, affecting 1 in 4, with rates particularly higher in those with SPMS, ...
Addressing depressive symptoms, particularly early in treatment ... decade (12.5 ± 8.4 years); the majority (58%) had relapsing-remitting MS (RRMS). In terms of education and income, a total ...
Research showed that HSCT in MS was associated with long-term improvements in quality of life but may cause short-term ...
At Sunday's Vanity Fair Oscar Party, Selma Blair's service dog shone brightest. The actress gushes over Scout and gives an ...
National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...
Certain immune cells in MS show abnormalities in activity and signs of reactions against the Epstein-Barr virus, a study says ...
Cladribine is part of a wider trend in the NHS toward embracing time-saving innovations. Similar treatments, such as the ...
The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
It has been approved by the National Institute for Health and Care Excellence (Nice) for people with relapsing-remitting MS. This means they have periods where their symptoms get worse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback